Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance
Guidance tracker
What ANURAS guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 13 Nov 2026 | Anupam Rasayan India Ltd filed the transcript of its Q2 and H1 FY27 earnings call held on November 6, 2026, for the quarter and half year ended September 30, 2026. Management said the Bliss GVS Pharma acquisition was completed on September 28, 2026, giving the company about 50.07% of Bliss GVS equity; consolidated... NSE copy | No results filed since | ||
| 19 Sep 2026 | Anupam Rasayan India Limited filed the outcome of its board meeting held on September 19, 2026, approving issuance of up to 16,000 secured, rated, unlisted, redeemable non-convertible debentures of INR 1,00,000 each, aggregating up to INR 160,00,00,000 (INR 160 crore), in one tranche on a private placement basis.... NSE copy | +12.7 % | +10.2 % | +2.8 % |
| 20 Aug 2026 | Anupam Rasayan India Ltd filed the transcript of its Q1 FY27 earnings call, held on August 14, 2026, for the quarter ended June 30, 2026. Management said consolidated total income rose 36% year-on-year to INR668 crores, with EBITDA of INR175 crores (26% margin) and PAT of INR51 crores, up 6% year-on-year.... NSE copy | +12.7 % | +10.2 % | +2.8 % |
| 14 Aug 2026 | Investor presentation for Q1 FY27 (quarter ended June 30, 2026) on the unaudited standalone and consolidated financial results, filed under Regulation 30 of the SEBI LODR Regulations. Consolidated total income for Q1 FY27 was Rs 6,675 Mn, up 36% year-on-year; consolidated EBITDA was Rs 1,749 Mn, up 35%;... NSE copy | +12.7 % | +10.2 % | +2.8 % |
| 30 May 2026 | Anupam Rasayan filed the transcript of its Q4 and FY26 earnings call held on May 25, 2026. Management said FY26 operating cash flow was INR334 crores and FY26 capex was INR315 crores, with all plants now commercialized and no major capex envisaged near term. Consolidated FY26 revenue from operations was INR2,384... NSE copy | +13.5 % | +34.8 % | -1.0 % |
| 19 Feb 2026 | Anupam Rasayan India filed the transcript of its Q3 FY26 / 9MFY26 earnings call held on February 14, 2026, on the unaudited results for the quarter and nine months ended December 31, 2025. Managing Director Anand Desai said consolidated 9MFY26 revenue was INR1,730 crores (up 84% Y-o-Y), EBITDA INR402 crores (up... NSE copy | -4.3 % | +27.1 % | +0.4 % |
| 19 Dec 2025 | Anupam Rasayan filed the transcript of its Investor Call on US Acquisition Update, held December 15, 2025. On December 9, 2025, the company signed a definitive agreement to acquire 100% equity in Jayhawk Fine Chemicals, a US-based specialty chemicals company from the CABB Group, headquartered in Kansas. Management... NSE copy | +74.0 % | +31.3 % | -6.5 % |
| 25 Oct 2025 | Anupam Rasayan India Ltd filed the transcript of its Q2 and H1 FY26 earnings call held on October 17, 2025, on the unaudited results for the quarter and half year ended September 30, 2025. Management reported consolidated revenue from operations of INR 731.4 crore in Q2 FY26 (up 148.8% YoY) and INR 1,217.2 crore in... NSE copy | +74.0 % | +31.3 % | -6.5 % |
| 19 Aug 2025 | Anupam Rasayan India Ltd filed the transcript of its Q1 FY26 earnings call held on August 14, 2025, on the unaudited results for the quarter ended June 30, 2025. Management said consolidated revenue from operations was INR486 crores, up 91% year-on-year, with consolidated EBITDA of INR129 crores (26.3% margin) and... NSE copy | +166.3 % | +148.8 % | +2.7 % |
| 28 May 2025 | Anupam Rasayan India Limited filed the transcript of its Q4 and FY25 earnings conference call, held on May 24, 2025, on the audited standalone and consolidated results. Management said consolidated revenue for Q4 FY25 was INR506 crores, up 22% Y-o-Y and 31% Q-o-Q, and FY25 consolidated revenue was INR1,448 crores,... NSE copy | +769.2 % | +91.1 % | +1.0 % |
| 19 Feb 2025 | Anupam Rasayan India Ltd filed the transcript of its Q3 FY'25 earnings call held on February 14, 2025, on unaudited standalone and consolidated results for the quarter and nine months ended December 31, 2024. Management said consolidated operating revenue for Q3 FY'25 was INR390 crores, up 32% Y-o-Y, with EBITDA of... NSE copy | +44.2 % | +24.7 % | +5.6 % |
| 13 Feb 2025 | Anupam Rasayan India Ltd filed its investor presentation on the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024 (Q3FY25). Consolidated total revenue for Q3FY25 was ₹3,866 Mn, up 31% quarter-on-quarter; consolidated PAT was ₹542 Mn, up 77%... NSE copy | +44.2 % | +24.7 % | +5.6 % |
| 20 Nov 2024 | Anupam Rasayan India Ltd filed the transcript of its Q2 & H1 FY25 earnings call held on November 15, 2024, covering unaudited results for the quarter and half year ended September 30, 2024. Management said consolidated operating revenue for Q2 FY25 was Rs.294 crores, down 25% YoY from Rs.392 crores, with EBITDA of... NSE copy | +53.1 % | +32.0 % | +0.9 % |
Filings tagged as guidance, newest first (13 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.
Governance
Management, auditors, ratings and legal matters
| Filed | Kind | What the filing says |
|---|---|---|
| 06 Nov 2026 | Legal or regulatory | Anupam Rasayan India Ltd filed its Q2 & H1 FY27 investor presentation (unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026). Consolidated total revenue for Q2 FY27 was ₹821 Cr (up 23% Q-o-Q); consolidated EBITDA ₹202 Cr; consolidated profit after tax ₹65 Cr.... NSE copy |
| 17 Sep 2026 | Legal or regulatory | Board of Anupam Rasayan India Ltd approved, at its meeting on September 17, 2026, execution of security documents for financing to wholly-owned subsidiary Mates Visa Consultancy Private Limited. Mates proposes to issue up to 30,000 senior secured unrated unlisted redeemable NCDs of INR 1,00,000 face value each,... NSE copy |
| 07 Sep 2026 | Management change | Board of Anupam Rasayan India Ltd approved the notice for its 23rd AGM on September 30, 2026 (video conference), with record date September 18, 2026 for final dividend for FY2025-26 if declared at the AGM. Board fixed September 23, 2026 as the voting eligibility cut-off date, speaker registration from September 24... NSE copy |
| 31 Aug 2026 | Credit rating | Anupam Rasayan India Ltd filed an intimation under Regulation 30 that Crisil Ratings has continued its ratings on the company's bank facilities and non-convertible debentures on 'Rating Watch with Developing Implications'. Rated bank loan facilities of Rs 1,620 crore: long term Crisil A+/Watch Developing and short... NSE copy |
| 14 Aug 2026 | Management change | Board outcome filed on August 14, 2026 (meeting held 08:48 to 09:36 IST) approving unaudited standalone and consolidated results for the quarter ended June 30, 2026, with limited review reports from the statutory auditor. Standalone revenue from operations for Q1 FY27 (quarter ended Jun-26) was INR 3,288.05... NSE copy |
| 03 Jun 2026 | Credit rating | Anupam Rasayan India Ltd filed an intimation under Regulation 30 of the SEBI Listing Regulations about a credit rating update by India Ratings and Research (Ind-Ra). Issuer rating is IND AA-/Rating Watch with Negative Implications, with the rating watch maintained. Bank loan facilities of INR 7,275 million (reduced... NSE copy |
| 03 Jun 2026 | Legal or regulatory, Credit rating | Anupam Rasayan India Ltd filed an intimation of credit rating action by Crisil Ratings Limited, dated June 2, 2026. Total bank loan facilities rated enhanced to Rs 1,620 crore from Rs 1,369.82 crore; long-term rating Crisil A+/Watch Developing and short-term rating Crisil A1/Watch Developing, both placed on Rating... NSE copy |
| 23 May 2026 | Legal or regulatory | Anupam Rasayan India Ltd filed an investor presentation dated May 2026 on its acquisition of Bliss GVS Pharma Limited, also to be hosted on the company website. The presentation describes Bliss GVS Pharma as an Indian pharmaceutical formulations company with 6 manufacturing facilities in Maharashtra, 150+ brands... NSE copy |
| 23 May 2026 | Management change | Outcome of board meeting held on May 23, 2026: audited standalone and consolidated financial results for quarter and year ended March 31, 2026 approved, with unmodified audit opinion from Natvarlal Vepari & Co. Board recommended final dividend of INR 1.5 per equity share (15% of face value of INR 10), subject to... NSE copy |
| 23 May 2026 | Management change | Board of Anupam Rasayan India Ltd approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026; statutory auditor Natvarlal Vepari & Co issued unmodified audit reports. Board recommended a final dividend of INR 1.5 per equity share (15% of face value of INR 10),... NSE copy |
| 06 Apr 2026 | Legal or regulatory | Anupam Rasayan India Ltd filed the outcome of its board meeting held on April 06, 2026. The board approved a postal ballot notice seeking shareholder consent, by remote e-voting only, for guarantees and security interests tied to a credit facility availed by Doriath S.à.r.l., effective if Doriath ceases to be a... NSE copy |
| 18 Mar 2026 | Credit rating | Anupam Rasayan India Ltd filed an intimation under Regulation 30 of the SEBI Listing Regulations dated March 18, 2026. Crisil Ratings Limited updated the credit rating on total bank loan facilities of Rs. 1369.82 crore. Long-term rating: Crisil A+/Stable, removed from 'Rating Watch with Negative Implications' and... NSE copy |
| 12 Feb 2026 | Legal or regulatory | Anupam Rasayan India Limited filed the outcome of its board meeting held on 12 February 2026, ratifying the acquisition of 100% equity in Doriath S.à r.l. (completed 10 February 2026) and 15% equity in Batam S.à r.l. (consideration paid, completion in process), both via Palaos S.à r.l. The board approved assigning... NSE copy |
| 18 Dec 2025 | Credit rating | Anupam Rasayan India Ltd filed an intimation under Regulation 30 of the SEBI Listing Regulations dated December 18, 2025. Crisil Ratings Limited updated the credit rating of the company, with total bank loan facilities rated at Rs. 1369.82 crore. Long-term rating: Crisil A+/Watch Negative (placed on 'Rating Watch... NSE copy |
| 18 Dec 2025 | Credit rating | Anupam Rasayan India Ltd filed an intimation under Regulation 30 of the SEBI Listing Regulations on credit rating action by India Ratings and Research (Ind-Ra). Ind-Ra placed the Long Term Issuer Rating of IND AA- on Rating Watch with Negative Implications. Ind-Ra placed the bank loan facilities (long term/short... NSE copy |
| 09 Dec 2025 | Legal or regulatory | Anupam Rasayan India Limited filed the outcome of its board meeting held on December 9, 2025. The board approved acquisition of 100% of Monitchem Kansas S.à r.l and its subsidiaries (Kansas HoldCo Inc., Kansas HoldCo 1, Inc., Jayhawk Fine Chemicals Corporation) from CABB Europe GmbH, and the SPA was executed the... NSE copy |
| 21 Nov 2025 | Management change | Board of Anupam Rasayan India Ltd approved a Postal Ballot Notice seeking shareholder approval, by special resolution, for appointment of Mr. Milind Madan Talathi (DIN: 07321958) as Non-Executive Independent Director for 3 consecutive years from September 25, 2025 to September 24, 2028. Postal Ballot notice to be... NSE copy |
| 01 Sep 2025 | Legal or regulatory, Management change | Board of Anupam Rasayan India Ltd approved appointment of Natvarlal Vepari & Co., Chartered Accountants, as Statutory Auditor, and M.D. Baid & Associates as Secretarial Auditor, subject to member approval at the 22nd AGM. Board approved re-appointment of Mr. Anand Sureshbhai Desai as Managing Director and Mrs. Mona... NSE copy |
| 17 Jan 2025 | Credit rating | Anupam Rasayan India Ltd filed an intimation under Regulation 30 of the SEBI Listing Regulations about a credit rating action by Crisil Ratings Limited. Long-term rating upgraded to Crisil A+/Stable from Crisil A/Positive; short-term rating reaffirmed at Crisil A1. Total bank loan facilities rated enhanced to Rs.... NSE copy |
| 21 Dec 2024 | Management change | Board meeting outcome dated December 21, 2024: board approved a Postal Ballot Notice seeking member consent, by remote e-voting only, to appoint four Non-Executive Independent Directors. Directors proposed: Ketan Paragji Desai and Gen. Bikram Singh (Retd.) for three years from November 09, 2024 to November 08,... NSE copy |
Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (20 in all). A list of what was filed, not a judgement of the company.